Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Richard Prins
AddedMar 31, 2024
UpdatedMay 31, 2026
Richard Prins

Richard Prins

Board Member, IGC Pharma

LinkedIn

Richard Prins's Career

IGC Pharma
IGC Pharma

Potomac, MD, US

Board Member· Board
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals

Rancho Cucamonga, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Richard Prins's Career

IGC Pharma
IGC Pharma
Public$15.3M502005Potomac, MD, US
Board Member· Board

Leadership at IGC Pharma

Ram MukundaRam MukundaBoard Member
Claudia GrimaldiClaudia GrimaldiBoard Member
John E LynchJohn E LynchBoard Member

Similar to IGC Pharma

IGC BIOIGC BIOBoston, MA, USAntibodiesest. 2014IGC BIOBoston, MA, US · est. 2014

IGC BIO: A Boston-based scientific platform for antibody creation, founded in 2014.

Seed · $4.7M5
IkariaIkariaHampton, NJ, USPharmaceuticalsest. 2006IkariaHampton, NJ, US · est. 2006

Ikaria, Inc. innovates and patents novel therapeutic pharmaceuticals.

Series D · $344.9M750
Pure Green PharmaceuticalsPure Green PharmaceuticalsWest Bloomfield Township, MI, USCannabinoid Therapies, PharmaceuticalsPure Green PharmaceuticalsWest Bloomfield Township, MI, US

Pure Green Pharmaceuticals crafts rapid-acting, water-soluble cannabinoid therapies for chronic conditions.

Series A · $5.4M6
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals
Public$300M1.6k1996Rancho Cucamonga, CA, US
Board Member· Board

Leadership at Amphastar Pharmaceuticals

Mary Z. LuoMary Z. LuoBoard Member
Michael A ZasloffMichael A ZasloffBoard Member
Jack YongfengJack YongfengFounder

Similar to Amphastar Pharmaceuticals

US Specialty FormulationsUS Specialty FormulationsBethlehem, PA, USPharmaceuticalsest. 2013US Specialty FormulationsBethlehem, PA, US · est. 2013

US Specialty Formulations produces FDA-approved sterile injectable pharmaceuticals for healthcare providers globally.

Angel · $75k14
Eagle PharmaceuticalsEagle PharmaceuticalsWoodcliff Lake, NJ, USInjectables, Pharmaceuticalsest. 2007Eagle PharmaceuticalsWoodcliff Lake, NJ, US · est. 2007

Eagle Pharmaceuticals Inc.: A specialty pharma company, developing and distributing critical care and oncology injectables.

Public · $12.3M134
CatalentCatalentSomerset, NJ, USPharmaceuticalsest. 2007CatalentSomerset, NJ, US · est. 2007

Catalent, Inc.: A leading global provider of pharmaceutical and biologic solutions, employing over 14,000.

Public · $1.1B19k

Richard Prins's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailDae Gyu ByunDae Gyu ByunBoard Member · NaverSeong-Sook HanSeong-Sook HanBoard Member · NaverRho Hyeok-JoonRho Hyeok-JoonBoard Member · Naver

People Similar to Richard Prins

Frank PicaFrank PicaCo-Founder · NativeDaniel P FlorinDaniel P FlorinBoard Member · PulmonxKathy ZhuKathy ZhuCo-Founder · Streamline AIJohn StewartJohn StewartBoard Member · SightGainRichard MackellarRichard MackellarBoard Member · Nano SteelLarry ZimplemanLarry ZimplemanBoard Member · Swiss Re